地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771997407
传真:18995651644
邮箱:sales@amyjet.com

艾美捷科技代理Cisbio 品牌。
Cisbio是一家专注于药物发现和生物分析的公司,提供创新的高通量筛选技术和生物分析工具,支持药物研发、毒理学研究和生物标志物发现。Cisbio公司采用 HTRF® 技术,实现高效、精确的药物发现和生物分析; 提供灵活的定制高通量筛选和生物分析服务,其产品用于药物筛选、靶点验证和药效评估;用于毒性测试和安全评估;用于生物标志物筛选和验证;用于细胞生物学、分子生物学和生物化学研究。。
Cisbio公司主要产品与服务:
(1)HTRF® 技术:提供基于 HTRF®(均相时间分辨荧光)技术的高通量筛选平台,用于药物发现和生物分析。
(2)生物分析工具:提供多种生物分析工具,如细胞活性检测、蛋白质相互作用分析和生物标志物检测。
(3)定制服务:根据客户需求,提供定制化的高通量筛选和生物分析服务。
(4)技术咨询与支持:提供药物发现和生物分析相关的咨询和技术支持服务。

艾美捷科技代理Vivitide品牌。
Vivitide是一家专注于为制药、生物技术和学术研究领域提供高质量多肽和肽相关服务的公司。Vivitide致力于支持科学家在药物发现、疫苗开发、诊断试剂和基础科学研究等领域的研究,提供从多肽合成到定制化解决方案的全流程服务。Vivitide业务领域:
(1)多肽合成:Vivitide 提供高质量的多肽合成服务,包括常规多肽、复杂多肽和修饰多肽。
(2)定制化多肽服务:根据客户的特定需求,提供定制化的多肽合成服务,包括不同长度、修饰和纯度的多肽。例如,荧光标记多肽、生物素标记多肽和磷酸化多肽。
(3)GMP 多肽生产:Vivitide 提供符合 GMP(药品生产质量管理规范)标准的多肽生产服务,支持临床试验和商业化生产。
(4)多肽文库:公司提供多肽文库服务,用于高通量筛选和药物发现。这些文库能够帮助科学家快速筛选出具有潜在活性的多肽。
(5)多肽分析和纯化:Vivitide 提供多肽分析和纯化服务,确保多肽的质量和纯度。这些服务包括 HPLC 分析、质谱分析和纯化。
<<< " data-original="http://peprotech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Vivitide品牌"> 艾美捷科技代理Vivitide品牌

艾美捷科技代理Giotto Biotech品牌。
Giotto Biotech公司是一家专注于核磁共振(NMR)相关技术的意大利生物技术公司。Giotto Biotech Srl是佛罗伦萨大学磁共振中心(CERM)的衍生品或分公司,与佛罗伦萨大学磁共振中心保持着密切的合作关系。Giotto Biotech专注于与核磁共振(NMR)有关的所有技术,致力于为学术和工业研究团体提供高质量的产品和服务。Giotto Biotech公司提供的产品和服务涵盖了多个领域:
(1)生物分子与有机合成:提供生物分子和有机合成相关的产品和服务,满足学术和工业研究的需求。
(2)代谢组学:利用NMR技术进行代谢组学研究,为客户提供代谢产物的定性和定量分析服务。
(3)NMR访问与信息技术:提供NMR仪器的访问权限以及相关的信息技术产品和服务,支持客户的NMR研究。
(4)定制生产服务:拥有大量的蛋白质表达产物,可以通过在大肠杆菌中的表达产生蛋白质。同时,公司还提供定制生产服务,包括重组蛋白质、肽类、有机分子和抗体等同位素标记的定制生产。
Giotto Biotech公司拥有丰富的蛋白质库,包括多种基质金属蛋白酶、S100蛋白质、Fe-S蛋白质等,可以满足客户在蛋白质研究方面的需求。Giotto Biotech注重产品质量和服务质量,通过质谱和NMR光谱等手段保证产品的纯度和质量,产品和服务广泛应用于生物医学、制药、农业和食品等多个领域。在生物医学领域,公司提供的代谢组学服务可以帮助研究人员进行疾病指纹图谱的构建和生物标志物的发现;在制药领域,公司可以利用NMR技术进行药物毒性的预测和药物作用机制的分析;在农业和食品领域,公司可以提供食品成分的分析和质量控制等服务。
<< " data-original="http://peprotech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Giotto Biotech品牌"> 艾美捷科技代理Giotto Biotech品牌
<艾美捷科技代理Microbs品牌全系列产品
Microbs是一家处于科技前沿的创新企业,专注于微生物检测与质量控制领域的研发与服务。Microbs的核心技术——IAN®超快速微生物检测方法,是公司在微生物检测领域的重大突破。这一技术巧妙融合固相细胞术与人工智能,颠覆了传统微生物检测耗时长的局限。以往需要数天的检测流程,如今借助IAN®,仅需15分钟就能准确计数细菌、酵母菌和霉菌,极大地提高了检测效率,为微生物QC实验室的生产力提升带来了革命性变化。
具体介绍一下优势:
● IAN®全自动解决方案:操作简便,无需专业知识,即可实现定性和定量检测,并给出客观结果,无需额外解释。这一特性使得微生物检测更加普及化和便捷化,降低了检测门槛,让更多企业和机构能够轻松开展微生物检测工作。
● TVC-CAP总菌群分析产品:无需管理多个耗材,让检测流程更加简化。它适用于液体基质,能够检测总需氧和厌氧菌群,LOD(检测限)达到1个微生物/样品,具备出色的可追溯性和数据完整性,符合21 CFR第11部分的要求。
● 部门广泛:用于制造业可助优化流程、缩短交货时间、提高生产能力;在质量管控方面可以降低质量成本,实现无缺陷、无召回的目标;在实验室里,实现更快的批次发布,推动检测自动化并确保可追溯性;在供应链环节,减少库存,节省库存成本,减少安全库存和所需的存储区域。
● 全过程应用:在生物负荷测试中严控中间产品、原材料及工艺用水质量;无菌测试保障产品无菌性;环境控制全方位监测拭子、人员与空气;不合格调查能快速溯源污染,为各行业提供全流程微生物检测与质控支持。
| 产品信息 | 描述 |
| A fully automated solution | To boost productivity in your microbial QC lab, Microbs is launching IAN®, an Ultra Rapid Microbiological Method allowing an accurate enumeration of bacteria, yeast and mold within minutes, |


艾美捷科技代理Zenogen Pharma品牌。
Zenogen Pharma公司主要研发生产治疗性抗体、疫苗佐剂及细胞冻存培养基
(1)治疗性抗体:
通过建立可有效生产特异性抗体和功能性抗体的技术平台,并将其扩展到新药以及其他产品和服务的开发,FZENOGEN公司为创造更好的药物和诊断药物做出了贡献。
(2)疫苗佐剂:
Zenogen Pharma公司开发了一种颗粒聚合物,能够大大增加免疫系统的激活。这种聚合物具有成功提高体液和细胞免疫力的能力,我们发现它具有发挥和安全使用效果的潜力。
(3)细胞冻存培养基:
CELLBANKER是一系列细胞冻存培养基,对于大多数细胞系,该培养基在解冻后可实现80%以上的细胞活力。
STEM-CELLBANKER® GMP grade 细胞冻存液
STEM-CELLBANKER® DMSO Free GMP grade 细胞冻存液
STEM-CELLBANKER® EX GMP grade 细胞冻存液
HSC-BANKER® GMP grade 细胞冻存液
CELLBANKER® 1 细胞冻存液
CELLBANKER® 2 细胞冻存液
CELLOTION® 细胞冻存液
< " data-original="http://peprotech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Zenogen Pharma品牌"> 艾美捷科技代理Zenogen Pharma品牌
艾美捷科技代理UnitedChem品牌。
UnitedChem位于美国新泽西州,是一家专注于化学试剂和精细化学品的公司,提供广泛的化学产品和定制合成服务。UnitedChem公司采用先进的生产和纯化技术,确保化学试剂和精细化学品的高纯度和高质量;产品广泛应用于制药、化工、材料科学。
UnitedChem产品包括:
(1)化学试剂:提供多种高纯度的化学试剂,包括有机试剂、无机试剂和分析试剂。
(2)精细化学品:提供多种精细化学品,用于制药、化工和材料科学领域。
(3)定制合成:根据客户需求,提供定制化的化学合成服务。
(4)技术咨询与支持:提供化学合成相关的咨询和技术支持服务。
<< " data-original="http://peprotech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理UnitedChem品牌"> 艾美捷科技代理UnitedChem品牌

艾美捷科技代理Biorelevant品牌。
Biorelevant公司成立于2006年,位于英国伦敦,是一家专注于开发和生产模拟人体胃肠道环境的体外溶出介质的公司,致力于为制药行业提供更准确、更可靠的药物溶出测试解决方案。Biorelevant公司可提供体外溶出介质:包括多种模拟人体胃肠道环境的溶出介质,用于药物溶出测试;还可以根据客户需求,提供定制化的溶出介质和测试方案并提供全面的技术支持和应用指导,帮助客户优化药物开发和测试流程。Biorelevant产品包括:FaSSIF、FeSSIF、FaSSGF、FeSSGF等多种模拟空腹和饱腹状态的溶出介质。其产品应用范围包括:
(1)药物开发,广泛应用于口服固体制剂的开发和优化,提高生物利用度和疗效;
(2)质量控制,用于药物生产过程中的质量控制,确保产品的一致性和稳定性;
(3)法规提交,支持药物注册和法规提交,提供符合监管要求的溶出测试数据。
<<<< " data-original="http://peprotech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Biorelevant品牌"> 艾美捷科技代理Biorelevant品牌
艾美捷科技代理Pfanstiehl品牌高纯度赋形剂、氨基酸、缓冲液组分。。
Meridian Bioscience是一家生命科学公司,开发、制造、销售各种创新的生命科学产品。提供用于人类、动物、植物和环境应用的免疫学和分子检测的关键生命科学原材料。Meridian Bioscience的生命科学部门,提供高质量分子试剂及抗原抗体。
Pfanstiehl公司生产符合cGMP标准的高纯度、低内毒素、低金属残留的注射级辅料和生物制药成分,用于生物加工、配方和特殊领域的各种应用。Pfanstiehl公司提供的赋形剂包括:蔗糖、海藻糖二水合物、D-半乳糖、麦芽糖一水合物、D-甘露糖、D-甘露醇、葡萄糖(葡萄糖);Pfanstiehl公司提供的氨基酸包括:精氨酸、精氨酸盐酸盐、组氨酸、盐酸组氨酸、L-蛋氨酸、甘氨酸、谷氨酰胺;Pfanstiehl公司提供的缓冲液成分:Tris Base、氨基甲烷盐酸盐、琥珀酸钠六水合物、琥珀酸。Pfanstiehl公司致力于各个多种应用场景的产品开发,包括:疫苗和生物稳定、蛋白质聚集减少、粘度降低、高浓度配方、高纯度低内毒素低金属注射级赋形剂、聚山梨酯降解缓解等。
< " data-original="http://peprotech.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Pfanstiehl品牌高纯度赋形剂、氨基酸、缓冲液组分"> 艾美捷科技代理Pfanstiehl品牌高纯度赋形剂、氨基酸、缓冲液组分
Neuromab是一家由NIH资助成立的单克隆抗体库。
The UC Davis/NIH NeuroMab Facility is a national monoclonal antibody-generating resource funded by the National Institutes of Health (NIH). The mission of the UC Davis/NIH NeuroMab Facility is to provide a unique neuroscience-based approach to generating mouse monoclonal antibodies optimized for use in mammalian brain (NeuroMabs). NeuroMabs are generated from mice immunized with synthetic and recombinant immunogens corresponding to components of the neuronal proteome as predicted from genomic and other large-scale cloning efforts. Comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain are incorporated into the UC Davis/NIH NeuroMab Facility screening procedure. This yields a subset of mouse mAbs that are optimized for use in brain (i.e., NeuroMabs): for immunohistochemical- based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks.
Neuromab的主要产品包括:
Array Tomography
Model Organisms
Disease Targets
产品列表:
| 抗体名称 |
| Anti-5-formylcytidine, NeuroMab clone N358/68 |
| Anti-5-hydroxymethylcytidine, NeuroMab clone N297/59 |
| Anti-6xHis, NeuroMab clone N144/14 |
| Anti-ADAM11, NeuroMab clone N441/35 |
| Anti-ADAM22-cytoplasmic, NeuroMab clone N46/30 |
| Anti-ADAM22-extracellular, NeuroMab clone N57/2 |
| Anti-AGPS neo-epitope, NeuroMab clone N444/63 |
| Anti-Aldh1L1 (Aldehyde dehydrogenase family 1 member L1), NeuroMab clone N103/39 |
| Anti-Aldh1L1 (Aldehyde dehydrogenase family 1 member L1), NeuroMab clone N103/31 |
| Anti-Alg13, NeuroMab clone N442/28 |
| Anti-Alpha-2C adrenergic receptor, NeuroMab clone N330A/80 |
| Anti-Alpha-2C adrenergic receptor, NeuroMab clone N330A/51 |
| Anti-AMIGO-1, NeuroMab clone L86/33 |
| Anti-AMIGO-1, NeuroMab clone L86/36 |
| Anti-AMIGO-1, NeuroMab clone L86A/37 |
| Anti-Ankyrin-B, NeuroMab clone N105/13 |
| Anti-Ankyrin-B, NeuroMab clone N105/17 |
| Anti-Ankyrin-G, NeuroMab clone N106/20 |
| Anti-Ankyrin-G, NeuroMab clone N106/36 |
| Anti-Ankyrin-G, NeuroMab clone N106/65 |
| Anti-Ankyrin-G, NeuroMab clone N106/43 |
| Anti-Ankyrin-R, NeuroMab clone N388A/10 |
| Anti-Ankyrin-R/G, NeuroMab clone N388A/27 |
| Anti-ANO3/TMEM16C, NeuroMab clone N454/91 |
| Anti-ANO5/TMEM16E, NeuroMab clone N421A/85 |
| Anti-ANO6/TMEM16F, NeuroMab clone N429/19 |
| Anti-ARHGAP4, NeuroMab clone N290B/25 |
| Anti-Arl13b, NeuroMab clone N295B/66 |
| Anti-Arx, NeuroMab clone N411/51 |
| Anti-ASIC1, NeuroMab clone N271/44 |
| Anti-ATAT1, NeuroMab clone N347/42 |
| Anti-Ataxin-1 11NQ, NeuroMab clone N76/8 |
| Anti-Ataxin-1 11NQ, NeuroMab clone N76/3 |
| Anti-Ataxin-1 wild-type, NeuroMab clone N65/37 |
| Anti-ATF4, NeuroMab clone N360A/24 |
| Anti-BAF53a, NeuroMab clone N336B/83 |
| Anti-BAF53b, NeuroMab clone N332B/15 |
| Anti-Bassoon, NeuroMab clone L124/59 |
| Anti-BBS3/Arl6, NeuroMab clone N302/10 |
| Anti-BBS5, NeuroMab clone N304B/115 |
| Anti-BDNF, NeuroMab clone N450/53 |
| Anti-Beta1-spectrin, NeuroMab clone N385/21 |
| Anti-Beta4-spectrin, NeuroMab clone N393/2 |
| Anti-Beta4-spectrin, NeuroMab clone N393/76 |
| Anti-BKBeta2 potassium channel subunit, NeuroMab clone N53/32 |
| Anti-BKBeta3a potassium channel subunit, NeuroMab clone N40B/18 |
| Anti-BKBeta4 potassium channel, NeuroMab clone L18A/3 |
| Anti-Botch1/Chac1, NeuroMab clone N116/14 |
| Anti-Bral1, NeuroMab clone N364/10 |
| Anti-Bral1, NeuroMab clone N364/42 |
| Anti-Brevican, NeuroMab clone N294A/6 |
| Anti-Brevican, NeuroMab clone N294A/10 |
| Anti-CALB1/calbindin, NeuroMab clone L109/39 |
| Anti-CALB1/calbindin, NeuroMab clone L109/57 |
| Anti-CALB2/calretinin, NeuroMab clone L122/6 |
| Anti-CALB2/calretinin, NeuroMab clone L122/68 |
| Anti-CASK scaffolding protein, NeuroMab clone K56A/50 |
| Anti-Caspr/paranodin/neurexin IV, NeuroMab clone K65/35 |
| Anti-Caspr2/paranodin, NeuroMab clone K67/25 |
| Anti-Cav1.2 calcium channel, NeuroMab clone L57/46 |
| Anti-Cav1.2, NeuroMab clone N263/31 |
| Anti-Cav1.3 calcium channel, NeuroMab clone L48A/9 |
| Anti-Cav1.3 calcium channel, NeuroMab clone N38/8 |
| Anti-Cav3.1 Ca2+ channel, NeuroMab clone N178A/9 |
| Anti-Cav3.2 calcium channel, NeuroMab clone N55/10 |
| Anti-Cav1 calcium channel, NeuroMab clone N7/18 |
| Anti-Cav尾2 calcium channel subunit, NeuroMab clone N8b/1 |
| Anti-Cav3 calcium channel, NeuroMab clone N473/36 |
| Anti-Cav尾4 calcium channel, NeuroMab clone N10/7 |
| Anti-Cdkl5, NeuroMab clone EA7 |
| Anti-CDY1/2, NeuroMab clone N143/38 |
| Anti-CDY1/2/L1/L2, NeuroMab clone N143/36 |
| Anti-Celf4/Brunol4, NeuroMab clone N446/80 |
| Anti-FOS, NeuroMab clone N486/32 |
| Anti-FOS, NeuroMab clone N486/76 |
| Anti-Clcn3, NeuroMab clone N258/5 |
| Anti-Clcn4, NeuroMab clone N222/6 |
| Anti-Clcn5, NeuroMab clone N406/47 |
| Anti-CLN3, NeuroMab clone N380/87 |
| Anti-CLN6, NeuroMab clone N400/24 |
| Anti-CNGA1/3 cyclic nucleotide-gated channel, NeuroMab clone L36/12 |
| Anti-Collybistin, NeuroMab clone L120/12 |
| Anti-Collybistin, NeuroMab clone L120/30 |
| Anti-Contactin/F3 scaffold protein, NeuroMab clone K73/20 |
| Anti-Copper-transporting ATPase 1, NeuroMab clone L60/4 |
| Anti-Copper-transporting ATPase 2 (Copper pump 2, Wilsons disease-associated protein, NeuroMab clone L62/29 |
| Anti-Co-Rest/RCOR1 Transcriptional Co-Repressor, NeuroMab clone K72/8 |
| Anti-DEPDC5, NeuroMab clone N463/52 |
| Anti-Dicer, NeuroMab clone N167/7 |
| Anti-DLX1 transcription factor, NeuroMab clone L43/40 |
| Anti-DNAH1, NeuroMab clone N251/14 |
| Anti-DNAH7, NeuroMab clone N250/21 |
| Anti-DNAIC1, NeuroMab clone UNC 65.56.18.11 |
| Anti-DNMT3L, NeuroMab clone N117/9 |
| Anti-Doc2b, NeuroMab clone N150/21 |
| Anti-Dopamine D2 receptor, NeuroMab clone N186/29 |
| Anti-Dopamine D3 receptor, NeuroMab clone N331/19 |
| Anti-EAAC1, NeuroMab clone N420/24 |
| Anti-FGF11 (Fibroblast growth factor 11), NeuroMab clone N92/14 |
| Anti-FGF12/FHF1, NeuroMab clone N94/17 |
| Anti-FGF13 (Fibroblast growth factor 13), NeuroMab clone N91/27 |
| Anti-FGF13B/FHF2B, NeuroMab clone N225A/10 |
| Anti-FGF14/FHF4, NeuroMab clone N56/21 |
| Anti-Fig4/Sac3, NeuroMab clone N202/7 |
| Anti-Flrt3, NeuroMab clone N353/13 |
| Anti-Foxi2, NeuroMab clone N349/96 |
| Anti-Foxi3, NeuroMab clone N359/28 |
| Anti-Frataxin, NeuroMab clone N191/7 |
| Anti-GABA-A-R-Alpha1, NeuroMab clone N95/35 |
| Anti-GABA-A-R-Alpha2, NeuroMab clone N399/19 |
| Anti-GABA-A-R-Alpha4, NeuroMab clone N398A/34 |
| Anti-GABA-A-R-Alpha5, NeuroMab clone N415/24 |
| Anti-GABA-A-R-Alpha6, NeuroMab clone N229A/32 |
| Anti-GABA-A-R-Beta1, NeuroMab clone N96/55 |
| Anti-GABA-A-R-Beta2/3, NeuroMab clone 62-3G1 |
| Anti-GABA-A-R-Beta3, NeuroMab clone N87/25 |
| Anti-Delta GABA-A receptor, NeuroMab clone N151/3 |
| Anti-GABA-A-R-Epsilon, NeuroMab clone N413/67 |
| Anti-GABA-A-R-Gamma2L, NeuroMab clone N452/69 |
| Anti-GABA-A-R-Gamma2L/S, NeuroMab clone N452/73 |
| Anti-GABA-A-R-Gamma2L/S, NeuroMab clone N452/30 |
| Anti-GABA-A-R-Pi, NeuroMab clone N431/64 |
| Anti- GABA-A-R-Theta, NeuroMab clone L123/109 |
| Anti-GABABR1 GABA-B receptor, NeuroMab clone N93A/49 |
| Anti-GABABR2 GABA-B receptor, NeuroMab clone N81/2 |
| Anti-GABABR2 GABA-B receptor, NeuroMab clone N81/37 |
| Anti-GAD65/67, NeuroMab clone L127/12 |
| Anti-GAD67, NeuroMab clone L127/8 |
| Anti-Gamma-protocadherin-A3, NeuroMab clone N144/17 |
| Anti-Gamma-protocadherin-B2, NeuroMab clone N148/30 |
| Anti-Gamma-protocadherin-C3, NeuroMab clone N174B/27 |
| Anti-Gamma-protocadherin-C4, NeuroMab clone N193A/13 |
| Anti-Gephyrin, NeuroMab clone L106/83 |
| Anti-Gephyrin, NeuroMab clone L106/93 |
| Anti-Gephyrin, NeuroMab clone L106/4 |
| Anti-GFAP, NeuroMab clone N206A/8 |
| Anti-GFAP-R416WT, NeuroMab clone N206B/9 |
| Anti-GFP (Green fluorescent protein), NeuroMab clone N86/8 |
| Anti-GFP (Green fluorescent protein), NeuroMab clone N86/38 |
| Anti-GFP (green fluorescent protein), NeuroMab clone N86/20 |
| Anti-GFP (green fluorescent protein), NeuroMab clone N86/44 |
| Anti-GIT1 scaffold protein, NeuroMab clone N39B/8 |
| Anti-GIT2 scaffold protein, NeuroMab clone N83/48 |
| Anti-GluA1/GluR1 glutamate receptor, NeuroMab clone N355/1 |
| Anti-GluA2/GluR2 glutamate receptor, NeuroMab clone L21/32 |
| Anti-KA2 kainate receptor, NeuroMab clone N279B/27 |
| Anti-GluN1/NR1 glutamate receptor, NeuroMab clone N308/48 |
| Anti-NR2A glutamate receptor, NeuroMab clone N327A/38 |
| Anti-GluN2A/NR2A glutamate receptor, NeuroMab clone N327/95 |
| Anti-GluN2B/NR2B glutamate receptor, NeuroMab clone N59/20 |
| Anti-GluN2B/NR2B glutamate receptor, NeuroMab clone N59/36 |
| Anti-GluN2C/NR2C, NeuroMab clone N422/18 |
| Anti- GluN3A/NR3A, NeuroMab clone N416/40 |
| Anti-Glycine receptor Alpha3, NeuroMab clone N424/45 |
| Anti-Glycine receptor Alpha3L, NeuroMab clone N424/48 |
| Anti-GRK6A/B, NeuroMab clone N142/28 |
| Anti-Gs protein alpha subunit, NeuroMab clone N192/12 |
| Anti-GST (Glutathione S-transferase), NeuroMab clone N100/13 |
| Anti-Haspin/GSG2, NeuroMab clone N128A/2 |
| Anti-HCN1 cyclic nucleotide-gated channel, NeuroMab clone N70/28 |
| Anti-HCN2 cyclic nucleotide-gated channel, NeuroMab clone N71/37 |
| Anti-HCN3 cyclic nucleotide-gated channel, NeuroMab clone N141/28 |
| Anti-HCN4 cyclic nucleotide-gated channel, NeuroMab clone N114/10 |
| Anti-Histone H2A.Z/V, NeuroMab clone N310/21 |
| Anti-Histone H2A.Z acetyl-Lys4/7/11, NeuroMab clone N299/39 |
| Anti-Histone H3.3, NeuroMab clone N158/28 |
| Anti-Histone H3 acetyl-Lys56, NeuroMab clone N307/12 |
| Anti-Histone H3-dimethyl-Arg8, NeuroMab clone N293/50 |
| Anti-Histone H3 pThr11, NeuroMab clone N123/19 |
| Anti-Histone H3 pThr11, NeuroMab clone N123/48 |
| Anti-Histone H4-dimethyl-Arg3, NeuroMab clone N309A/21 |
| Anti-Homer1L, NeuroMab clone L113/27 |
| Anti-Homer1L, NeuroMab clone L113/13 |
| Anti-Homer1, NeuroMab clone L113/130 |
| Anti-ICK, NeuroMab clone N451/73 |
| Anti-Iduna/RNF146, NeuroMab clone N201/35 |
| Anti-INPP4b, NeuroMab clone N171/17 |
| Anti IP3 receptor type 1 NeuroMab clone L24/18 |
| Anti-IRSp53/BAIAP2, NeuroMab clone L117/1 |
| Anti-JIP-2/IB-2, NeuroMab clone N135/37 |
| Anti-JMJD2A, NeuroMab clone N154/32 |
| Anti-KCC2 transporter, NeuroMab clone N1/66 |
| Anti-KCC2 transporter, NeuroMab clone N1/12 |
| Anti-KChIP1 potassium channel, NeuroMab clone K55/7 |
| Anti-KChIP2 potassium channel subunit, NeuroMab clone K60/73 |
| Anti-KChIP3 potassium channel, NeuroMab clone K66/38 |
| Anti-KChIP4 K+ channel, NeuroMab clone N423/75 |
| Anti-KCNT1/Slo2.2/Slack K+ channel, NeuroMab clone N3/26 |
| Anti-KCNT2/Slo2.1/Slick sodium- and chloride-activated ATP sensitive potassium channel, NeuroMab clone N11/33 |
| Anti-KCNU1/Slo3 pH-sensitive maxi potassium channel, NeuroMab clone N2/16 |
| Anti-Keyhole limpet hemocyanin, NeuroMab clone N132A/12 |
| Anti-Kir2.1 potassium channel, NeuroMab clone N112B/14 |
| Anti-Kir2.2 potassium channel, NeuroMab clone N124B/38 |
| Anti-Kir2.3 potassium channel, NeuroMab clone N25/35 |
| Anti-Kir2.4 potassium channel, NeuroMab clone N465/11 |
| Anti-Kir3.3 potassium channel, NeuroMab clone N455/15 |
| Anti-Kir6.1 potassium channel, NeuroMab clone N366/60 |
| Anti-Kir6.2 potassium channel, NeuroMab clone N363/71 |
| Anti-Kirrel3 short and long, NeuroMab clone N321C/49 |
| Anti-Kirrel3 short isoform 3, NeuroMab clone N320/48 |
| Anti-Kv1.1 potassium channel subunit, NeuroMab clone K20/78 |
| Anti-Kv1.1 potassium channel (external), NeuroMab clone K36/15 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone K14/16 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone L76/36 |
| Anti-Kv1.3 potassium channel, NeuroMab clone L23/27 |
| Anti-Kv1.4 potassium channel subunit, NeuroMab clone K13/31 |
| Anti-Kv1.4 potassium channel (extracellular), NeuroMab clone L71/5 |
| Anti-Kv1.5 potassium channel, NeuroMab clone K7/45 |
| Anti-Kv1.6 potassium channel subunit, NeuroMab clone K19/36 |
| Anti-Kv1.7 potassium channel, NeuroMab clone N471/27 |
| Anti-Kv11.3 potassium channel, NeuroMab clone N447/24 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone L83/11 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone K89/34 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone L80/21 |
| Anti-Kv2.1 potassium channel (external), NeuroMab clone K39/25 |
| Anti-Kv2.2 potassium channel, NeuroMab clone K37/89 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372C/51 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372B/60 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372B/1 |
| Anti-Kv3.1b potassium channel, NeuroMab clone N16b/8 |
| Anti-Kv3.2 potassium channel, NeuroMab clone N410/17 |
| Anti-Kv3.3 potassium channel, NeuroMab clone N375/67 |
| Anti-Kv3.4 potassium channel, NeuroMab clone N72/16 |
| Anti-Kv4.2 potassium channel subunit, NeuroMab clone L28/4 |
| Anti-Kv4.2 potassium channel (external), NeuroMab clone K57/1 |
| Anti-Kv4.3 potassium channel subunit, NeuroMab clone K75/41 |
| Anti-Kv4.3 potassium channel subunit, NeuroMab clone K75/30 |
| Anti-Kv6.1 potassium channel, NeuroMab clone N474/27 |
| Anti-Kv6.4 potassium channel, NeuroMab clone N458/10 |
| Anti-KCNQ1 potassium channel, NeuroMab clone N37A/10 |
| Anti-KCNQ2 potassium channel, NeuroMab clone N26A/23 |
| Anti-KCNQ4 potassium channel, NeuroMab clone N43/6 |
| Anti-Kv8.2 potassium channel, NeuroMab clone N448/88 |
| Anti-Kv8.2 potassium channel, NeuroMab clone N448/50 |
| Anti-Kv9.1 potassium channel, NeuroMab clone N461/19 |
| Anti-Kv9.2 potassium channel, NeuroMab clone N460/19 |
| Anti-Kvβ1.1 potassium channel subunit, NeuroMab clone K9/40 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone K47/42 |
| Anti-Kv尾2 potassium channel, NeuroMab clone K17/70 |
| Anti-Laforin, NeuroMab clone N84/37 |
| Anti-LAR/PTPRF, NeuroMab clone N165/38 |
| Anti-Lgi1, NeuroMab clone N283/7 |
| Anti-Lhx6.1, NeuroMab clone N228A/16 |
| Anti-LRP4 (cytoplasmic), NeuroMab clone N164/6 |
| Anti-LRP4 (extracellular), NeuroMab clone N207/27 |
| Anti-LRRK1, NeuroMab clone N341/37 |
| Anti-LRRK1, NeuroMab clone N341/12 |
| Anti-LRRK2/Dardarin, NeuroMab clone N241A/34 |
| Anti-LRRK2/Dardarin, NeuroMab clone N231B/34 |
| Anti-LRRK2/Dardarin, NeuroMab clone 8G10 |
| Anti-LRRK2/Dardarin, NeuroMab clone N138/6 |
| Anti-LRRK2/Dardarin-pSer910, NeuroMab clone 1D8 |
| Anti-LRRTM2, NeuroMab clone N209C/35 |
| Anti-LRRTM4, NeuroMab clone N205B/22 |
| Anti-Mad3, NeuroMab clone N129A/6 |
| Anti-Mad3, NeuroMab clone N129/15 |
| Anti-Malin, NeuroMab clone N85/18 |
| Anti-MBP (Maltose-binding protein), NeuroMab clone N128A/4 |
| Anti-MAP3K12, NeuroMab clone N377/20 |
| Anti-MAP3K12, NeuroMab clone N377/83 |
| Anti-MECP2, NeuroMab clone N227/21 |
| Anti-MESD, NeuroMab clone N88/12 |
| Anti-MFF, NeuroMab clone N382/14 |
| Anti-MFF (exon 1), NeuroMab clone N382/69 |
| Anti-MGL, NeuroMab clone N90/20 |
| Anti-mGluR1/5 (group I) glutamate receptor, NeuroMab clone N75/3 |
| Anti- mGluR1/5 (group I) glutamate receptor, NeuroMab clone N75/33 |
| Anti-Miro2, NeuroMab clone N384/63 |
| Anti-MiRP4 potassium channel, NeuroMab clone N472/88 |
| Anti-Mitofusin-1 (Mfn1), NeuroMab clone N111/24 |
| Anti-Mitofusin-2 (Mfn2), NeuroMab clone N153/5 |
| Anti-MMACHC, NeuroMab clone N230/21 |
| Anti-MMP9 metalloproteinase, NeuroMab clone L51/82 |
| Anti-MOG, NeuroMab clone L94/54 |
| Anti-Mortalin/GRP75, NeuroMab clone N52A/42 |
| Anti-MPP8, NeuroMab clone N119/44 |
| Anti-NALCN, NeuroMab clone N185/7 |
| Anti-Nav1.1 sodium channel, NeuroMab clone K74/71 |
| Anti-Nav1.2 sodium channel, NeuroMab clone K69/3 |
| Anti-Nav1.4 sodium channel, NeuroMab clone N255/38 |
| Anti-Nav1.5 sodium channel, NeuroMab clone N397/19 |
| Anti-Nav1.6 sodium channel, NeuroMab clone K87A/10 |
| Anti-Nav1.7 sodium channel, NeuroMab clone N68/6 |
| Anti-Nav1.8 sodium channel, NeuroMab clone N134/12 |
| Anti-Navbeta1 Na+ channel, NeuroMab clone N405/74 |
| Anti-Navbeta2 Na+ channel, NeuroMab clone N395/68 |
| Anti-Navbeta3 Na+ channel, NeuroMab clone N396/29 |
| Anti-Navbeta4 sodium channel, NeuroMab clone N168/6 |
| Anti-NCKX4, NeuroMab clone N414/25 |
| Anti-Neuregulin-CRD (Cysteine-rich domain, Type III), NeuroMab clone N126B/31 |
| Anti-Neuregulin-HBD (Heparin-binding domain, Type I/II), NeuroMab clone N120A/9 |
| Anti-Neurexin-1-Beta, NeuroMab clone N170A/1 |
| Anti-Neurexin-1-Beta, NeuroMab clone N170A/26 |
| Anti-Neuroligin-1, NeuroMab clone N97A/31 |
| Anti-Neuroligin-2, NeuroMab clone L107/39 |
| Anti-Neuroligin-3, NeuroMab clone N110/29 |
| Anti-Neuroligin-4*, NeuroMab clone N98/47 |
| Anti-Neuroligin-4*, NeuroMab clone N98/7 |
| Anti-NGL-1 (Netrin-G1 ligand), NeuroMab clone N49A/21 |
| Anti-NGL-2 (Netrin-G2 ligand) NeuroMab clone N50/36 |
| Anti-NGL-3 (Netrin-G3 ligand), NeuroMab clone N51/6 |
| Anti-NKCC1, NeuroMab clone N161/20 |
| Anti-NOS1/nNOS, NeuroMab clone L121/25 |
| Anti-NOS1/nNOS, NeuroMab clone L121/42 |
| Anti-Notch1, NeuroMab clone N253/32 |
| Anti-Npas4, NeuroMab clone N408/62 |
| Anti-Npas4, NeuroMab clone N408/79 |
| Anti-Neuropeptide Y, NeuroMab clone L115/13 |
| Anti-NPY2R, NeuroMab clone L119/106 |
| Anti-NrCAM, NeuroMab clone N343/26 |
| Anti-NSD1, NeuroMab clone N312/10 |
| Anti-NSD3, NeuroMab clone N348/82 |
| Anti-OCRL/INPP5b, NeuroMab clone N166A/26 |
| Anti-Olig1, NeuroMab clone N149/25 |
| Anti-Pan-Ankyrin, NeuroMab clone N388A/60 |
| Anti-Pancortin, NeuroMab clone K96/7 |
| Anti-Pan-FHF-A, NeuroMab clone N235/22 |
| Anti-Pan-Gamma-protocadherin-A, NeuroMab clone N144/32 |
| Anti-Pan-Gamma-protocadherin, NeuroMab clone N159/5 |
| Anti-Pan-GRK, NeuroMab clone N145/20 |
| Anti-Pan-KChIP potassium channel, NeuroMab clone K55/82 |
| Anti-Pan-Kv potassium channel, NeuroMab clone K40/17 |
| Anti-Pan-Kvbeta potassium channel, NeuroMab clone K25/73 |
| Anti-Pan-MAGUK scaffold proteins, NeuroMab clone K28/86 |
| Anti-Pan-Nav1 sodium channel, NeuroMab clone N419/40 |
| Anti-Pan-Nav1 sodium channel, NeuroMab clone N419/78 |
| Anti-pan-Neurofascin, NeuroMab clone L11A/41 |
| Anti-Pan-Neurofascin (external), NeuroMab clone A12/18 |
| Anti-Pannexin-2, NeuroMab clone N121A/1 |
| Anti-Pannexin-2, NeuroMab clone N121A/31 |
| Anti-Pan-PTPR, NeuroMab clone N165/43 |
| Anti-Pan-QKI, NeuroMab clone N147/6 |
| Anti-Pan-SAPAP, NeuroMab clone N127/31 |
| Anti-pan-Shank (SH3 and multiple ankyrin repeat domains protein) scaffold protein, NeuroMab clone N23B/49 |
| Anti-Pan-Synapsin, NeuroMab clone L125/129 |
| Anti-Pan-Thyroid hormone receptor, NeuroMab clone N403/63 |
| Anti-PARIS/ZNF746, NeuroMab clone N196/16 |
| Anti-Parvalbumin, NeuroMab clone L114/3 |
| Anti-Parvalbumin, NeuroMab clone L114/81 |
| Anti-PEX6, NeuroMab clone N233/8 |
| Anti-PEX7, NeuroMab clone N232/9 |
| Anti-Phosphoserine-2-OEt, NeuroMab clone N257/25 |
| Anti-Phosphoserine-2-OH, NeuroMab clone N259/48 |
| Anti-Phosphoserine-2-OMe, NeuroMab clone N262/16 |
| Anti-PhyH/PAHX, NeuroMab clone N210/5 |
| Anti-PICK1 scaffold, NeuroMab clone L20/8 |
| Anti-PINK1, NeuroMab clone N4/15 |
| Anti-PINK1, NeuroMab clone N4/49 |
| Anti-PINK1, NeuroMab clone N4/19 |
| Anti-PINK1, NeuroMab clone N357/6 |
| Anti-Proser1, NeuroMab clone N456/39 |
| Anti-Prrt2, NeuroMab clone N485/22 |
| Anti-PSD-93/Chapsyn-110 scaffold protein, NeuroMab clone N18/30 |
| Anti-PSD-93/Chapsyn-110 scaffold protein, NeuroMab clone N18/28 |
| Anti-PSD-95 MAGUK scaffold protein, NeuroMab clone K28/43 |
| Anti-PSD-95 MAGUK scaffold protein, NeuroMab clone K28/74 |
| Anti-QKI-5-NLS, NeuroMab clone N195A/16 |
| Anti-QKI-6, NeuroMab clone N182/17 |
| Anti-QKI-7, NeuroMab clone N183/15 |
| Anti-QKI-7b, NeuroMab clone N194/11 |
| Anti-RBM17/SPF45, NeuroMab clone N219/5 |
| Anti-REEP, NeuroMab clone N326D/13 |
| Anti-REEP1, NeuroMab clone N345/51 |
| Anti-REEP1/2, NeuroMab clone N326D/29 |
| Anti-REEP2, NeuroMab clone N326D/2 |
| Anti-Rem2, NeuroMab clone N324/2 |
| Anti-RGS14, NeuroMab clone N133/21 |
| Anti-RGS14, NeuroMab clone N133/35 |
| Anti-Rufy3, NeuroMab clone N483/84 |
| Anti-Rufy3, NeuroMab clone N483/126 |
| Anti-Rufy3, NeuroMab clone N483/26 |
| Anti-S100A5, NeuroMab clone N176A/35 |
| Anti-SALM2 synaptic adhesion-like molecule, NeuroMab clone N52B/27 |
| Anti-SALM5/LRFN5, NeuroMab clone N140A/12 |
| Anti-SAP102 MAGUK scaffold protein, NeuroMab clone N19/2 |
| Anti-SAP97 scaffold protein, NeuroMab clone K64/15 |
| Anti-SAPAP1, NeuroMab clone N238/29 |
| Anti-SAPAP1, NeuroMab clone N238/30 |
| Anti-SAPAP1/2, NeuroMab clone N238/31 |
| Anti-SAPAP2, NeuroMab clone N459/84 |
| Anti-SAPAP3, NeuroMab clone L126/93 |
| Anti-SCG10/stathmin-2, NeuroMab clone L5/1 |
| Anti-SH3GL1, NeuroMab clone K51/1 |
| Anti-Shank1/ SPANK-1/Synamon/SSTRIP scaffold protein, NeuroMab clone N22/21 |
| Anti-Shank1 and Shank3, NeuroMab clone N367/51 |
| Anti-Shank2/ProSAP1/Spank-3/CortBP1 scaffold protein,NeuroMab clone N23B/6 |
| Anti-Shank3 scaffold protein, NeuroMab clone N69/46 |
| Anti-Shank3, NeuroMab clone N367/62 |
| Anti-SK2 potassium channel, NeuroMab clone K78/29 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/23 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/48 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/60 |
| Anti-Snapin (SNAP25 binding protein), NeuroMab clone L8/15 |
| Anti-SNAT1 Neurotransmitter Transporter NeuroMab clone N104/37 |
| Anti-SNAT1 Neurotransmitter Transporter NeuroMab clone N104/32 |
| Anti-SST/Somatostatin, NeuroMab clone L111/118 |
| Anti-S-tag, NeuroMab clone N56/9 |
| Anti-Stonin-2, NeuroMab clone N346/9 |
| Anti-SUR1, NeuroMab clone N289/16 |
| Anti-SUR1 and SUR2B, NeuroMab clone N323A/31 |
| Anti-SUR2A, NeuroMab clone N319A/14 |
| Anti-SUR2B, NeuroMab clone N323B/20 |
| Anti-SVOP, NeuroMab clone N356/9 |
| Anti-SVOP, NeuroMab clone N356/23 |
| Anti-Synapsin-III, NeuroMab clone L125/121 |
| Anti-Synaptotagmin-10, NeuroMab clone N269/73 |
| Anti-Synaptotagmin-12, NeuroMab clone N277/7 |
| Anti-Synaptotagmin-3, NeuroMab clone N278/19 |
| Anti-Synaptotagmin-5, NeuroMab clone N274/8 |
| Anti-Synaptotagmin-6, NeuroMab clone N270/47 |
| Anti-Synaptotagmin-7, NeuroMab clone N275/14 |
| Anti-Synaptotagmin-9, NeuroMab clone N276A/15 |
| Anti-SynCAM1 cell adhesion molecule, NeuroMab clone L45/30 |
| Anti-SynCAM4, NeuroMab clone N244/5 |
| Anti-SynDIG1/Tmem90b, NeuroMab clone L42/17 |
| Anti-SynDIG3/Tmem91, NeuroMab clone N160/21 |
| Anti-SynDIG4, NeuroMab clone L102/45 |
| Anti-Tafazzin, NeuroMab clone N173B/13 |
| Anti-TALK1 potassium channel, NeuroMab clone N466/14 |
| Anti-TARPGamma2/Stargazin, NeuroMab clone N245/1 |
| Anti-TARPGamma2/4/8, NeuroMab clone N245/36 |
| Anti-TASK1 potassium channel, NeuroMab clone N374/48 |
| Anti-Tauro-GM2, NeuroMab clone N175/9 |
| Anti-THAP1, NeuroMab clone N325B/65 |
| Anti-THIK-2 potassium channel, NeuroMab clone N468/37 |
| Anti-Thioredoxin, NeuroMab clone N245/44 |
| Anti-Thorase (Atad1), NeuroMab clone N125/10 |
| Anti-Thyroid hormone receptor beta1, NeuroMab clone N402/13 |
| Anti-Thyroid hormone receptor beta1, NeuroMab clone N402/46 |
| Anti- TRAAK potassium channel, NeuroMab clone N445/27 |
| Anti-TRAK1, NeuroMab clone N389/9 |
| Anti-TRAK2, NeuroMab clone N390/43 |
| Anti-TRESK potassium channel, NeuroMab clone N467/1 |
| Anti-TRIP8b (constant), NeuroMab clone N212/7 |
| Anti-TRIP8b (constant), NeuroMab clone N212/17 |
| Anti-TRIP8b (exon 1a/5 junction), NeuroMab clone N291C/22 |
| Anti-TRIP8b (exon 1b), NeuroMab clone N212A/34 |
| Anti-TRIP8b (exon 4), NeuroMab clone N212/3 |
| Anti-TrpC1 calcium channel, NeuroMab clone 1F1 |
| Anti-TrpC4 calcium channel, NeuroMab clone N77/15 |
| Anti-TrpC5 calcium channel, NeuroMab clone N67/15 |
| Anti-TrpC7 calcium channel, NeuroMab clone N64A/36 |
| Anti-TrpM4, NeuroMab clone L88/86 |
| Anti-TrpM6, NeuroMab clone N470/22 |
| Anti-TrpM7 ion channel and Ser/Thr kinase, NeuroMab clone N74/25 |
| Anti-TRPML3/Mucolipin-3, NeuroMab clone N268/19 |
| Anti-TrpV1, NeuroMab clone N221/17 |
| Anti-TrpV1, NeuroMab clone N221/12 |
| Anti-TrpV3 cation channel, NeuroMab clone N15/4 |
| Anti-TrpV3 cation channel, NeuroMab clone N15/39 |
| Anti-TWIK-2 potassium channel, NeuroMab clone N469/28 |
| Anti-Uncx, NeuroMab clone N155/9 |
| Anti-VAChT vesicular acetylcholine transporter, NeuroMab clone N6/38 |
| Anti-VAChT, NeuroMab clone N425/45 |
| Anti-VAPA, NeuroMab clone N479/12 |
| Anti-VAPA, NeuroMab clone N479/22 |
| Anti-VAPA/B, NeuroMab clone N479/107 |
| Anti-VDAC1, NeuroMab clone N152B/23 |
| Anti-Versican, NeuroMab clone N351/23 |
| Anti-Versican, NeuroMab clone N351/24 |
| Anti-VGAT, NeuroMab clone L118/80 |
| Anti-VGAT, NeuroMab clone L118/66 |
| Anti-VGlut1, NeuroMab clone N28/9 |
| Anti-VGlut2, NeuroMab clone N29/29 |
| Anti-VGlut3, NeuroMab clone N34/34 |
| Anti-VIP, NeuroMab clone L108/92 |
| Anti-VMAT1, NeuroMab clone N440/21 |
| Anti-VMAT1, NeuroMab clone N440/61 |
| Anti-Slc18a2/VMAT2, NeuroMab clone N449/73 |
| Anti-Zebrafish VSP/TPTE, NeuroMab clone N432/21 |
| Anti-Zebrafish VSP/TPTE, NeuroMab clone N432/63 |
| Anti-WAVE1/SCAR, NeuroMab clone K91/36 |
| Anti-WNK1, NeuroMab clone N391/68 |
| Anti-WRN, NeuroMab clone N428/12 |
| Zebrafish PSD Marker, NeuroMab clone N286/74 |
| Anti-Zinedin/Striatin-4, NeuroMab clone K88/64 |
| Anti-ZIP3, NeuroMab clone N476/9 |
| Anti-ZNF423, NeuroMab clone N328B/37 |

艾美捷科技代理日本Nissui品牌培养基产品。
岛津诊断是岛津公司(Shimadzu Corporation)在医疗诊断领域的专业分支。岛津公司自1875年创业以来,始终秉承创始人岛津源藏的创业宗旨“以科学技术向社会做贡献”,并在分析测试仪器、医疗仪器等领域不断推陈出新。岛津诊断作为其重要组成部分,专注于为医疗领域提供先进的诊断设备和技术支持。岛津诊断拥有丰富的产品线,涵盖多个医疗诊断领域。其产品线可能包括但不限于:
(1)临床检验设备:如生化分析仪、血液分析仪等,用于临床实验室的常规检验。
(2)医学影像设备:岛津公司在医疗影像领域也有显著成就,如X光机、CT等影像诊断设备,为医生提供准确的医学影像支持。
在技术实力方面,岛津诊断依托岛津公司的强大研发能力,不断推出创新技术和产品。其设备通常具有高精度、高稳定性和易于操作的特点,为医生提供可靠的诊断依据。
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:18771149750
邮箱:sales@amyjet.com
0.1966